Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. 2009

Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan. shigeki@mail.pharm.tohoku.ac.jp

Galantamine, a novel Alzheimer's drug, is known to inhibit acetylcholinesterase activity and potentiate nicotinic acetylcholine receptor (nAChR) in the brain. We previously reported that galantamine potentiates the NMDA-induced currents in primary cultured rat cortical neurons. We now studied the effects of galantamine on long-term potentiation (LTP) in the rat hippocampal CA1 regions. The field excitatory postsynaptic potentials (fEPSPs) were induced by stimulation of the Schaffer collateral/commissural pathways in the hippocampal CA1 region. Treatment with 0.01-10 microM galantamine did not affect the slope of fEPSPs in the CA1 region. Galantamine treatment increased calcium/calmodulin-dependent protein kinase II (CaMKII) and protein kinase Calpha (PKCalpha) activities with a bell-shaped dose-response curve peaked at 1 microM, thereby increasing the phosphorylation of AMPA receptor, myristoylated alanine-rich protein kinase C, and NMDA receptor as downstream substrates of CaMKII and/or PKCalpha. By contrast, galatamine treatment did not affect protein kinase A activity. Consistent with the bell-shaped CaMKII and PKCalpha activation, galantamine treatment enhanced LTP in the hippocampal CA1 regions with the same bell-shaped dose-response curve. Furthermore, LTP potentiation induced by galantamine treatment at 1 microM was closely associated with both CaMKII and PKC activation with concomitant increase in phosphorylation of their downstream substrates except for synapsin I. In addition, the enhancement of LTP by galantamine was accompanied with alpha7-type nAChR activation. These results suggest that galantamine potentiates NMDA receptor-dependent LTP through alpha7-type nAChR activation, by which the postsynaptic CaMKII and PKC are activated.

UI MeSH Term Description Entries
D008297 Male Males
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D009434 Neural Pathways Neural tracts connecting one part of the nervous system with another. Neural Interconnections,Interconnection, Neural,Interconnections, Neural,Neural Interconnection,Neural Pathway,Pathway, Neural,Pathways, Neural
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005702 Galantamine A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. Galantamin,Galanthamine,Lycoremine,Reminyl,Galanthamine Hydrobromide,Nivalin,Nivaline,Razadyne
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D000076250 Myristoylated Alanine-Rich C Kinase Substrate A membrane and ACTIN CYTOSKELETON associated, N-terminal myristoylated protein that binds CALMODULIN and is a prominent substrate for PROTEIN KINASE C. Both phosphorylation and poly(ADP)-ribosylation inhibit its F-ACTIN crosslinking activity; phosphorylation also causes MARCKS to relocate from the membrane to cytoplasm. ACAMP-81,MARCKS Protein,Myristoylated Alanine Rich C Kinase Substrate

Related Publications

Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
July 2000, Journal of neurochemistry,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
November 2004, Journal of neurophysiology,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
June 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
November 1995, Proceedings of the National Academy of Sciences of the United States of America,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
April 2006, Journal of neurochemistry,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
April 1993, The Journal of biological chemistry,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
October 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
June 2001, The Journal of biological chemistry,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
May 1992, Nature,
Shigeki Moriguchi, and Norifumi Shioda, and Feng Han, and Jay Z Yeh, and Toshio Narahashi, and Kohji Fukunaga
March 1989, The Biochemical journal,
Copied contents to your clipboard!